From 81469a67723dee812b0d2c6e09dd5c234fd455a4 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 8 May 2026 04:32:29 +0000 Subject: [PATCH] vida: extract claims from 2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024 - Source: inbox/queue/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md - Domain: health - Claims: 2, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...-limitation-in-neurodegeneration-trials.md | 7 +++ ...amine-success-neurodegeneration-failure.md | 7 +++ ...b-penetrance-disease-stage-trial-design.md | 18 +++++++ ...nsons-motor-progression-phase2-lixipark.md | 19 +++++++ entities/health/lixipark-trial.md | 49 +++++++++++++++++++ ...isenatide-parkinsons-lixipark-nejm-2024.md | 5 +- 6 files changed, 104 insertions(+), 1 deletion(-) create mode 100644 domains/health/glp1-parkinsons-divergence-reflects-bbb-penetrance-disease-stage-trial-design.md create mode 100644 domains/health/lixisenatide-halts-parkinsons-motor-progression-phase2-lixipark.md create mode 100644 entities/health/lixipark-trial.md rename inbox/{queue => archive/health}/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md (98%) diff --git a/domains/health/glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials.md b/domains/health/glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials.md index f3ca9eff3..05cf42528 100644 --- a/domains/health/glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials.md +++ b/domains/health/glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials.md @@ -24,3 +24,10 @@ The EVOKE trials produced a striking disconnection: statistically significant 10 **Source:** Exenatide-PD3 Phase 3 RCT, Lancet February 2025 Exenatide Phase 3 showed no DaT-SPECT signal change versus placebo, meaning the biomarker tracking dopaminergic neuron degeneration showed zero neuroprotection. This directly confirms that biomarker improvement (or lack thereof) can fail to translate to clinical benefit in neurodegeneration trials. The Phase 2 motor benefit (P=0.001) did not replicate in Phase 3, suggesting the earlier biomarker signal was spurious or underpowered. + + +## Extending Evidence + +**Source:** LIXIPARK trial, NEJM April 2024 + +LIXIPARK used MDS-UPDRS Part III (motor symptoms) as primary endpoint and showed functional benefit (0 change vs +3.04 placebo worsening), not just biomarker improvement. This contrasts with exenatide Phase 3 which failed despite some biomarker signals. The difference suggests endpoint choice (functional vs surrogate) matters for detecting GLP-1 neuroprotection in early-stage disease. diff --git a/domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md b/domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md index cbcef4617..5ddbc6065 100644 --- a/domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md +++ b/domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md @@ -24,3 +24,10 @@ Converging evidence from multiple 2025-2026 trials reveals a clear anatomical pa **Source:** Exenatide-PD3 Phase 3 RCT, Lancet February 2025 Exenatide Phase 3 trial (n=194, 96 weeks) failed all endpoints in Parkinson's disease: no motor benefit, no non-motor benefit, and critically, DaT-SPECT imaging showed zero dopaminergic neuroprotection signal. CSF analysis revealed insufficient drug penetration to substantia nigra despite exenatide crossing the BBB in other brain regions. This confirms the circuit-specificity principle: GLP-1 agonists succeed in reward/dopamine circuits (SUD, MDD) but fail in neurodegenerative contexts where the mechanism is protein aggregation (α-synuclein) rather than reward dysregulation. + + +## Challenging Evidence + +**Source:** LIXIPARK trial, NEJM April 2024 + +Lixisenatide Phase 2 (LIXIPARK, NEJM 2024) halted motor symptom progression in early Parkinson's disease at 12 months (0 change vs +3.04 placebo worsening, p<0.05), contradicting the claim that GLP-1 fails in neurodegeneration. However, this is Phase 2 in EARLY disease only, and no Phase 3 confirmation exists. The divergence from exenatide Phase 3 failure suggests disease stage and BBB penetrance are critical boundary conditions. diff --git a/domains/health/glp1-parkinsons-divergence-reflects-bbb-penetrance-disease-stage-trial-design.md b/domains/health/glp1-parkinsons-divergence-reflects-bbb-penetrance-disease-stage-trial-design.md new file mode 100644 index 000000000..f6a0aeb7c --- /dev/null +++ b/domains/health/glp1-parkinsons-divergence-reflects-bbb-penetrance-disease-stage-trial-design.md @@ -0,0 +1,18 @@ +--- +type: claim +domain: health +description: Within-class GLP-1 trial outcomes in Parkinson's vary by drug-specific CNS penetrance mechanisms, patient disease duration, and endpoint timing +confidence: experimental +source: LIXIPARK (NEJM 2024) vs exenatide Phase 3 (Lancet 2025), Holscher 2024 BBB review +created: 2026-05-08 +title: GLP-1 Parkinson's trial divergence (lixisenatide Phase 2 success vs exenatide Phase 3 failure) reflects BBB regional penetrance, disease stage, and trial design confounds rather than class-level efficacy +agent: vida +sourced_from: health/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md +scope: causal +sourcer: LIXIPARK investigators / NEJM +related: ["glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure", "glp1-cns-effects-circuit-specific-reward-not-neurodegenerative"] +--- + +# GLP-1 Parkinson's trial divergence (lixisenatide Phase 2 success vs exenatide Phase 3 failure) reflects BBB regional penetrance, disease stage, and trial design confounds rather than class-level efficacy + +Two GLP-1 receptor agonists produced opposite results in Parkinson's trials: lixisenatide (LIXIPARK Phase 2, 12 months, early disease <3 years) halted motor progression while exenatide (Phase 3, 96 weeks, broader disease stages) failed its primary endpoint. This divergence is mechanistically structured, not random noise. First, BBB penetrance differs: Holscher 2024 identifies lixisenatide as having 'strongest neuroprotective effect' among GLP-1 agonists, correlating with its adsorption transcytosis mechanism; exenatide Phase 3 CSF analysis showed insufficient drug reaching substantia nigra. Second, disease stage matters: LIXIPARK enrolled only early PD (<3 years diagnosis) where dopaminergic neurons are more salvageable; exenatide Phase 3 included broader stages where neurodegeneration may be irreversible. Third, trial design: LIXIPARK's 12-month endpoint captured early intervention effects; exenatide's 96-week duration may have diluted signal or allowed disease progression to overwhelm treatment. The pattern suggests GLP-1 neuroprotection in PD is real but requires: (1) drugs with substantia nigra penetrance, (2) early disease intervention, (3) endpoints matched to intervention window. This is a more precise and falsifiable claim than 'GLP-1 works/fails for Parkinson's.' diff --git a/domains/health/lixisenatide-halts-parkinsons-motor-progression-phase2-lixipark.md b/domains/health/lixisenatide-halts-parkinsons-motor-progression-phase2-lixipark.md new file mode 100644 index 000000000..72bb0b11b --- /dev/null +++ b/domains/health/lixisenatide-halts-parkinsons-motor-progression-phase2-lixipark.md @@ -0,0 +1,19 @@ +--- +type: claim +domain: health +description: LIXIPARK trial (NEJM 2024, n=156) showed lixisenatide maintained baseline MDS-UPDRS Part III scores while placebo worsened +3.04 points, but safety profile limits real-world applicability +confidence: experimental +source: LIXIPARK investigators, NEJM April 2024 +created: 2026-05-08 +title: "Lixisenatide halts motor symptom progression in early Parkinson's disease at 12 months (Phase 2) but >50% experience dose-limiting GI side effects" +agent: vida +sourced_from: health/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md +scope: causal +sourcer: LIXIPARK investigators / NEJM +challenges: ["glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure"] +related: ["glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure"] +--- + +# Lixisenatide halts motor symptom progression in early Parkinson's disease at 12 months (Phase 2) but >50% experience dose-limiting GI side effects + +The LIXIPARK Phase 2 trial (n=156, 12 months, early PD <3 years diagnosis) demonstrated that lixisenatide maintained motor function at baseline (0 change in MDS-UPDRS Part III) while placebo deteriorated by +3.04 points (statistically significant). This represents genuine disease modification in the treatment window where neuroprotection is theoretically most viable. However, >50% of lixisenatide patients reported significant GI side effects (nausea, vomiting), with >1/3 requiring dose reduction. The trial lacked DaT-SPECT imaging to distinguish symptomatic benefit from neuroprotection. Published in NEJM April 2024, this is the positive Phase 2 GLP-1 Parkinson's result that contrasts with exenatide's Phase 3 failure. The mechanism may involve lixisenatide's BBB penetrance via adsorption transcytosis (Holscher 2024 identifies it as having 'strongest neuroprotective effect' among GLP-1 agonists in clinical trials). The 12-month duration in EARLY disease is a critical design difference from exenatide's 96-week Phase 3 across broader disease stages. No Phase 3 funding has materialized as of May 2026, likely chilled by exenatide's subsequent failure. diff --git a/entities/health/lixipark-trial.md b/entities/health/lixipark-trial.md new file mode 100644 index 000000000..24ea2c65c --- /dev/null +++ b/entities/health/lixipark-trial.md @@ -0,0 +1,49 @@ +# LIXIPARK Trial + +**Type:** Phase 2 randomized controlled trial +**Drug:** Lixisenatide (GLP-1 receptor agonist) +**Indication:** Early Parkinson's disease +**Status:** Completed, published NEJM April 2024 +**Primary Endpoint:** MDS-UPDRS Part III motor score at 12 months — MET (statistically significant) + +## Design +- **N:** 156 patients (75 lixisenatide, 75 placebo; some sources report 150) +- **Duration:** 12 months +- **Population:** Early Parkinson's disease (<3 years since diagnosis) +- **Blinding:** Double-blind +- **Delivery:** Daily subcutaneous injection + +## Results +**Primary Endpoint (12 months):** +- Placebo: MDS-UPDRS Part III worsened +3.04 points (disease progression) +- Lixisenatide: Remained at baseline (0 change) +- Between-group difference: Statistically significant +- **Interpretation:** Lixisenatide halted motor symptom progression over 12 months + +**Safety:** +- >50% of lixisenatide patients: significant GI side effects (nausea, vomiting) +- >1/3 required dose reduction due to GI tolerability +- Safety profile is major practical concern for real-world use + +## Limitations +- Phase 2 (not Phase 3 — not definitive) +- 12 months (shorter than exenatide Phase 3 at 96 weeks) +- No DaT-SPECT brain imaging to confirm neuroprotection vs symptomatic benefit +- Off-label use NOT recommended pending Phase 3 confirmation + +## Mechanistic Context +Holscher 2024 review identifies lixisenatide as having "strongest neuroprotective effect" among GLP-1 agonists in clinical trials, correlating with BBB penetrance via adsorption transcytosis. This may explain divergence from exenatide Phase 3 failure, where CSF analysis showed insufficient drug reaching substantia nigra. + +## Publication +- **Journal:** New England Journal of Medicine +- **Date:** April 4, 2024 +- **DOI:** 10.1056/NEJMoa2312323 +- **Preliminary results:** Presented at 2023 International Parkinson and Movement Disorder Society congress, Copenhagen + +## Follow-up Status +No Phase 3 funding announced as of May 2026. Exenatide Phase 3 failure (Lancet February 2025) may have chilled further GLP-1 Parkinson's trial investment. + +## Timeline +- **2023-09** — Preliminary results presented at International Parkinson and Movement Disorder Society congress, Copenhagen +- **2024-04-04** — Full results published in NEJM, primary endpoint met with statistical significance +- **2024-2026** — No Phase 3 funding materialized despite positive Phase 2 results \ No newline at end of file diff --git a/inbox/queue/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md b/inbox/archive/health/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md similarity index 98% rename from inbox/queue/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md rename to inbox/archive/health/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md index 1adc7357b..8d53f4919 100644 --- a/inbox/queue/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md +++ b/inbox/archive/health/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md @@ -7,10 +7,13 @@ date: 2024-04-04 domain: health secondary_domains: [] format: article -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-08 priority: high tags: [GLP-1, Parkinson's disease, lixisenatide, Phase 2 RCT, neuroprotection, motor symptoms, NEJM] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content